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Abstract
Background: The variability of visit-to-visit (VVV) in systolic blood pressure (SBP) and diastolic blood pressure (DBP)
is proved as a predictor of renal function deterioration in patients with non-diabetic chronic kidney disease. The
purpose of this study was to investigate the relationship of the variability in SBP and the magnitude of renal function
impairment for normal renal function patients in the first 10-years diagnosed with type II diabetes mellitus (DM).
Methods: We retrospectively reviewed the electronic medical records of 789 patients who were first diagnosed with
diabetes mellitus during 2000–2002 and regularly followed for 10 years with a total of 53,284 clinic visits. The stages
of Chronic Kidney Disease (CKD) of every patient were determined using estimated glomerular filtration rate. The
occurrence of nephropathy was defined in those patients whose CKD stages elevated equal or larger than three.
Results: Patients were categorized according to the VVV of systolic and diastolic BP into three groups. Patients with
high VVV of both SBP and DBP had a 2.44 fold (95% CI: 1.88–3.17, p < 0.001) increased risk of renal function impairment
compared with patients with low VVV of both SBP and DBP. Risk of renal function impairment for patients with high
VVV of either SBP or DBP had a 1.43-fold increase (95% CI: 1.08–1.89, p = 0.012) compared with patients with low VVV
of both SBP and DBP. Cox regression analysis also demonstrated that every 1-year increase of DM diagnosed age
significantly raised the risk of renal function impairment with a hazard ration of 1.05 (95% CI: 1.04–1.06, p < 0.001).
Conclusions: Not only VVV of SBP but also VVV in DBP is correlated with diabetic nephropathy in the first decade for
patients diagnosed with type 2 DM.
Keywords: Blood pressure control, Chronic kidney disease, Electronic medical record, Hypertension
* Correspondence: yehccl@cgmh.org.tw
1Department of Thoracic and Cardiovascular Surgery, Chang Gung Memorial
Hospital, 222 Mai-Chin Road, Keelung 204, Taiwan, Republic of China
2College of Medicine, Chang Gung University, Tao-Yuan, Taiwan, Republic of
China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Yeh et al. BMC Nephrology  (2017) 18:99 
DOI 10.1186/s12882-017-0514-9
Background
Diabetes mellitus (DM) is the primary cause of end stage
renal disease [1]. In adults aged 18 years or older with
DM, 71% are reported to have hypertension [1], a major
risk of microvascular complications and cardiovascular
mortality [2]. In patients with DM, several risk factors
including mean blood pressure (BP), albuminuria, high
hemoglobin A1c and serum cholesterol have been shown
to accelerate the progression of chronic kidney disease
(CKD) [3, 4].
In diabetic patients with CKD, the decline of the glom-
erular filtration rate (GFR) is highly variable, ranging
from 2 to 20 mL/min/year [3]. The risk factors for losing
filtration power, such as hypertension, proteinuria, gly-
cemic control and lipids, have not been studied exten-
sively. Controversy existed as some of these factors
contributed to renal function impairment in diabetic pa-
tients [5]. To identify the risk factors of renal function
deterioration is important for development of prevention
modalities in diabetic patients’ treatment. In clinical
diabetic treatment guideline [6], absolute BP is used as
a therapeutic target to prevent clinical stroke and heart
disease, as well as CKD with paucity of evidence [7].
Recently, the visit-to-visit variability (VVV) of systolic
BP (SBP) has been shown to be a novel risk factor for
development of renal function decline in non-diabetic
CKD [8], progression of albuminuria and nephropathy
in patients with type II DM [9, 10], and deterioration of
renal function for stage 3–4 diabetic CKD patients [4].
Although it is widely known that average blood pressure
is related to renal function deterioration. However, little
is known about the long-term association of VVV of
SBP and diastolic BP (DBP) with renal function impair-
ment in patients with normal renal function at the
diagnosis of DM. The association between VVV of BP
and CKD generally consider SBP measurements at a
few time points and in a short to medium follow-up
period, limiting the appreciation of the full impact of
SBP and DBP on CKD. BP fluctuation across long
periods and its effect on renal function impairment in
diabetic patients with normal renal function are typic-
ally not considered. Therefore, we evaluated the long-
term relationship between the VVV of SBP and DBP
and the change of the CKD stage in patients from the
beginning of diagnosed with type 2 DM.
Methods
Patients and study design
We retrospectively collect the 10-year measurements of
blood pressure, body weight, body height, and laboratory
datas at every outpatient clinic visit of 789 patients who
were first diagnosed with type 2 DM during 2000–2002
at Chang Gung Memorial Hospital, Keelung. Type 2
DM was diagnosed in accordance with the criteria of
American Diabetes Association [11]. Body mass index
(BMI) was defined as weight (kilograms) divided by
height (meters) squared. Patients were classified as non-
smokers, former smokers, or current smokers according
to the electronic medical record. Patients with advanced
renal dysfunction (serum Cr more than 2.0 mg/dL) be-
fore diagnosed with DM were excluded from this study.
Cardiovascular disease (CVD) included coronary artery
disease or myocardial infarction, and ischemic stroke or
transient ischemic attack [12] that resulted from ath-
erosclerosis after type II diabetes was diagnosed. The
coronary artery disease was confirmed by coronary
angiography and the ischemic stroke or transient ische-
mic attack was confirmed by computed tomography or
clinical symptoms. The definition of dyslipidemia was
either total cholesterol >200 mg/dL, low density lipo-
protein cholesterol >100 mg/dL, low density lipoprotein
cholesterol <50 mg/dL in female and <40 mg/dL in
male, or triglyceride >150 mg/dL which were based on
the standards of the laboratory in our hospital. Hyper-
tension was defined as systolic pressure ≥130 mmHg or
diastolic pressure ≥ 80 mmHg in diabetic patients [13].
We then evaluated relationships of variability in blood
pressure to change of CKD stage during the 10-year fol-
low-up period. The study was conducted in accordance
with the Declaration of Helsinki and was approved by the
Institutional Review Board of Chang Gung Memorial
Hospital; informed consent was waived. Blood pressure
measurements at every outpatient clinic visit throughout
the follow-up period were recorded. Fasting serum total
cholesterol, low-density lipoprotein, high-density lipo-
protein, and triglyceride concentrations were assessed
using standard enzymatic methods. Hemoglobin A1c was
assayed using high-performance liquid chromatography
and expressed with the unit defined by the National
Glycohemoglobin Standardization Program.
Definition of BP variability
Throughout the 10-year consecutive visits from the
beginning of the observation period, the mean office BP
and the VVV of SBP and DBP (expressed as within-
individual standard deviation (SD) were calculated. The
BP instability indice was expressed as the delta BP, which
was defined as a difference between the maximum and
the minimum BP, through all 10-year visits [14].
Definition of CKD and renal function impairment
Serial serum creatinine data were collected and eGFR
was determined by the abbreviated CKD Epidemiology
Collaboration equation [15]. CKD was defined as a
decreased estimated glomerular filtration rate (eGFR)
(<60 ml/min per 1.73 m2) for 3 months. CKD stage
was defined in accordance with the guideline of
National Kidney Foundation [16], which stage 1, 2, 3, 4,
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and 5 had a eGFR of ≥ 90, 60 to 90, 30 to 59, 15–29, and
< 15 ml/min per 1.73 m2 or commencement of dialysis
therapy, respectively. Renal function impairment was de-
fined as two or more CKD stages (from stage 1 or 2 to
stage 3–5 or 4–5, respectively) deterioration without
recovery.
Statistical analysis
Means and frequencies of potential confounding vari-
ables were calculated. The relationships between vari-
ability in SBP and DBP, as well as other variables, and
renal function impairment were examined by Pearson’s
correlation analyses. To examine the effects of various
factors on the deterioration of renal function, the follow-
ing factors were considered simultaneously as independ-
ent variables for Cox multiple regression analysis: age of
DM diagnosed, sex, BMI, average SBP and DBP, SD of
SBP and DBP, hemoglobin A1c, total cholesterol, trigly-
ceride, smoking status, presence of CVD, hypertension
and dyslipidemia. All continuous variables are presented
as the mean ± SD or absolute number. A P value <0.05
was considered statistically significant. The area under
each receiver operating curve (ROC) and 95% confi-
dence intervals (CI) were estimated to compare the rela-
tive ability of SD of SBP and DBP to identify risk of
renal function impairment in diabetic patients. Optimal
cut-off points for SD of SBP and DBP indicator were de-
termined [17]. The collinearity among average SBP and
DBP, SD of SBP and DBP, and delta SBP and DBP was
estimated using variance inflation factor [18].
Results
Eight hundred and twenty-five patients were first diag-
nosed with DM from 2000 to 2002. Thirty-six patients
who were died or loss of follow-up were excluded. None
of these patients died from renal failure. The characteris-
tics of the 789 patients, who were first diagnosed with
DM from 2000 to 2002 and followed for 10 years, en-
rolled in this study are shown in Table 1. The total num-
ber of measurements of BP, BMI, HbA1c, lipid profile,
and serum creatinine throughout 10- year of data collec-
tion was 49739, 35432, 27424, 9327, and 14123, respect-
ively. The characteristics of the study patients were
shown in Table 1. The overall mean age of the patients
diagnosed with DM was 53.3 ± 10.5 years. At baseline,
the mean initial serum creatinine was 0.93 ± 0.45 mg/dL,
the mean initial eGFR was 88.6 ± 22.7 mL/min per
1.73 m2, and the mean office SBP and DBP was 136.6 ±
10.1 and 73.5 ± 6.3 mm Hg, respectively. The median
observation period was 4451 ± 453 days. At the end of
the observation period, the mean serum creatinine level
was 1.10 ± 0.81 mg/dL and the mean eGFR was 75.1 ±
27.6 mL/min per 1.73 m2. The 10 year mean change of
CKD stage was 1.2 ± 0.8.
Cox regression analyses revealed that the SD of SBP was
positively correlated with the occurrence of renal function
impairment (P < 0.001, Hazard ratio (HR) = 1.063, 95%
CI = 1.028–1.100), as well as the SD of DBP (P < 0.024,
HR = 1.081, 95% CI = 1.010–1.156). The age of DM first
diagnosed had also positively correlated with the
occurrence of renal function impairment after 10-year
follow-up (P < 0.001, HR = 1.048, 95% CI = 1.036–1.060).
Our results found that maximum, minimum or delta of
SBP and DBP had no significant independent correlations
Table 1 Patients’ demographic and clinical characteristics
Patients (n) 789
Age at diabetes diagnosis (years) 53.3 ± 10.5
Sex (male/female) 373/416
Smoking (none/former/current) 598/45/146
Hypertension (%) 597 (75.7)
Hyperlipidemia (%) 758 (96.1)
Body mass index (kg/m2) 26.8 ± 3.9
Mean number of measurements 45.0 ± 24.5
Mean SBP (mmHg) 137 ± 10
Mean number of measurement 63.0 ± 28.9
SD of SBP (mmHg) 14.7 ± 3.6
Delta SBP (mmHg) 71.7 ± 25.0
Mean DBP (mmHg) 73.5 ± 6.3
SD of DBP (mmHg) 7.4 ± 2.0





Mean number of measurements 34.8 ± 10.9
Total cholesterol (mg/dL) 193.4 ± 28.6
Mean number of measurements 11.9 ± 5.8
High-density lipoprotein (mg/dL) 38.5 ± 10.7
Low-density lipoprotein (mg/dL) 118.7 ± 20.3
Triglyceride (mg/dL) 149.8 ± 113.8
Initial eGFR (mL/min/1.73 m2) 88.6 ± 22.7
Mean number of measurements 17.9 ± 6.7
Final eGFR (mL/min/1.73 m2) 75.1 ± 27.6
Clinical Events during10-year follow-up
CVD a (%) 115 (14.6)
Interval from diabetes diagnosis (years) 5.2 ± 3.1
Change in CKD stage 1.2 ± 0.7
Renal function impairment (%) 309 (39.2)
CKD stage 4 or 5 (%) 83 (10.5)
Total follow-up period (days) 4451 ± 453
Abbreviations: SBP systolic blood pressure, DBP diastolic blood pressure, SD
standard deviation, eGFR estimated glomerular filtration rate, CVD cardiovascular
disease, CKD chronic kidney disease
aDefined as coronary artery disease or myocardial infarction, and ischemic
stroke or transient ischemic attack
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between renal function impairment after 10-year of DM
diagnosed. And multiple regression analysis demonstrated
that other factors, such as mean or SD of hemoglobin
A1c, BMI, total cholesterol, low-density lipoprotein,
high-density lipoprotein, triglyceride, were not inde-
pendently correlated with the occurrence of renal func-
tion impairment, as shown in Table 2.
For clinical application, we calculated the area under
the ROC curves for the SD of SBP (0.87 ± 0.02) and DBP
(0.85 ± 0.03) and categorized patients into high or low
SD of SBP or DBP. The best cut-point BP was calculated
based on the Youden Index [19], which was calculated
as sensitivity + specificity − 1. Cut-off points of SD of
SBP and DBP, where sensitivity approximates specificity
for renal function impairment, are 16.3 and 7.6 mmHg,
respectively. Patients with SD of SBP and DBP higher
than the cut-off values were defined as high VVV of SBP
and DBP, respectively. Patients were grouped as low
VVV of SBP and DBP, high VVV of SBP or DBP, and
high VVV of SBP and DBP. The characteristics of pa-
tients in these three groups were shown in Table 3.
Using univariate analysis, the age of DM diagnosed,
hypertension history, BMI, mean SBP and DBP, SD of
SBP and DBP, delta SBP and DBP, and mean hemoglobin
A1c, and initial eGFR were significantly different be-
tween these three groups of patients.
After 10 years of DM diagnosis, the patients with high
VVV of both SBP and DBP had the highest percentage
of peripheral artery disease, cerebrovascular disease, cor-
onary artery disease or myocardial infarction, transient
ischemic attack or stroke, and the highest percentage of
patients with renal function impairment, which all were
significantly different among these three groups. Cox
multivariate regression revealed that only the age of DM
diagnosed and the group of VVV of SBP and DBP were
significant risk factors for development of renal function
impairment after 10-year follow-up, as shown in Table 4.
All the variance inflation factors among mean, SD and
delta of SBP and DBP were less than three, which ex-
cluded the collinearity between these factors. The risk of
renal function impairment in patients with high VVV of
both SBP and DBP significantly increased 2.773 fold (p
< 0.001, 95% CI = 2.128–3.612) compared that of pa-
tients with low VVV of both SBP and DBP. Whereas the
risk of renal function impairment in patients with wither
high VVV of SBP or DBP increased 1.587 fold (p = 0.001,
95% CI = 1.195–2.107) compared that of patients with
low VVV of both SBP and DBP. The renal function in-
tact survival curve for these three groups of patients was
shown in Fig. 1.
Discussion
This study showed that VVV of both SBP and DBP were
significantly associated with the change to CKD stage in
the first decade of patients diagnosed with DM, whereas
mean office SBP/DBP, delta SBP/DBP, mean serum lipid
profile, mean hemoglobin A1c concentration, and SD of
hemoglobin A1c concentration were not correlated with
the occurrence of renal function impairment. To the
best of our knowledge, this is the first study to explore
the association of the VVV of SBP and DBP and renal
function decline in the first decade of patients with DM.
In the present study, not only the VVV of SBP was
significantly associated with the change of CKD stage,
but the VVV of DBP was also significantly associated
with the occurrence of renal function impairment in our
study patients group. For the first time, our result dem-
onstrated that a VVV of SBP higher than 16.3 mmHg or
a VVV of DBP higher than 7.6 mmHg would signifi-
cantly increase the risk of decline of renal function in
Table 2 Multivariate Cox regression analyses of renal function
impairment in 789 patients after 10-year diabetes diagnosis
Independent variable β P Value
Sex (female = 0) 0.250 0.081
Age of DM diagnosed 0.047 <0.001
Non-smoking
Former smoker 0.004 0.990
Current smoker 0.098 0.560
Hypertension 0.687 0.001
Dyslipidemia 0.119 0.772
Mean SBP 0.023 0.435
SD of SBP 0.062 <0.001
CV of SBP 2.414 0.944
Delta of SBP −0.005 0.227
Mean DBP −0.048 0.269
SD of DBP 0.077 0.024
CV of DBP −0.047 0.856
Delta of DBP 0.002 0.787
Mean BMI 0.84 0.047
SD of BMI −0.293 0.119
Mean HbA1c −0.167 0.251
SD of HbA1c 0.214 0.485
Mean serum cholesterol 0.004 0.482
SD of serum cholesterol −0.008 0.111
Mean serum LDL −0.013 0.053
SD of serum LDL −0.001 0.860
Mean serum HDL 0.024 0.357
SD of serum HDL 0.006 0.726
Mean serum triglyceride −0.004 0.047
SD of serum triglyceride 0.002 0.509
Abbreviations: HbA1c hemoglobin A1c, SBP systolic blood pressure, DBP diastolic
blood pressure, SD standard deviation, CV coefficient of variation, BMI body mass
index, LDL low density lipoprotein, HDL high density lipoprotein
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the first decade of patients diagnosed with DM. Further-
more, with both high VVV of SBP and DBP would even
increase the risk of renal function impairment to 2.773
fold compared with those patients with both low VVV
of SBP and DBP.
Our results are in accordance with other study find-
ings, which showed a significant association between
VVV of BP and progression of nondiabetic CKD [8, 9].
However, in contrast with our findings, the other study
with a small sample size (69 patients) and short study
period (32 months) from Yokota et al. reported negative
association between VVV of BP and renal function
deterioration in CKD patients [4]. The other large co-
hort study included 114,900 adults with CKD stage 3–4
Table 3 Demographic and clinical characteristics compared between patients with low VVV of SBP and DBP, high VVV of SBP or
DBP, and high VVV of SBP and DBP
Low VVV of SBP and
DBP group (n = 370)
High VVV of SBP or
DBP group (n = 241)
High VVV of SBP and
DBP group (n = 178)
P
Age at diabetes diagnosis (years) 52.8 ± 10.1 51.5 ± 10.4 56.6 ± 10.6 <0.001
Sex (male/female) 172 (46.5) 120 (49.8) 81 (47.3) 0.629
Smoking (none/former/current) 287/17/66 179/18/44 132/10/36 0.594
Hypertension (%) 237 (64.1) 199 (82.6) 161 (90.4) <0.001
Hyperlipidemia (%) 358 (96.8) 227 (94.2) 173 (97.2) 0.191
Body mass index (kg/m2) 26.4 ± 3.6 27.3 ± 4.2 27.0 ± 3.9 0.007
Mean SBP (mmHg) 133.9 ± 9.6 137.3 ± 9.2 141.2 ± 10.6 <0.001
Mean number of measurements 60.4 ± 26.0 63.8 ± 29.9 67.8 ± 32.6 0.019
SD of SBP (mmHg) 12.3 ± 2.0 14.9 ± 2.6 19.3 ± 2.8 <0.001
Delta SBP (mmHg) 59.3 ± 15.1 73.3 ± 23.0 95.2 ± 26.6 <0.001
Mean DBP (mmHg) 71.6 ± 5.5 75.3 ± 5.9 74.8 ± 7.2 <0.001
SD of DBP (mmHg) 6.0 ± 0.9 8.1 ± 1.4 9.6 ± 1.7 <0.001










Mean number of measurements 36.1 ± 10.8 34.5 ± 10.5 32.3 ± 11.2 0.001
Total cholesterol (mg/dL) 191.8 ± 26.7 193.0 ± 27.0 197.1 ± 33.9 0.132
Mean number of measurements 12.1 ± 5.9 11.9 ± 5.7 11.2 ± 5.8 0.220
High-density lipoprotein (mg/dL) 38.9 ± 10.6 38.1 ± 10.8 38.4 ± 10.7 0.678
Low-density lipoprotein (mg/dL) 118.3 ± 19.2 119.3 ± 20.9 118.8 ± 21.6 0.832
Triglyceride (mg/dL) 141.0 ± 117.4 155.6 ± 90.3 160.1 ± 132.4 0.119
Initial eGFR (mL/min/1.73 m2) 81.4 ± 26.0 77.5 ± 25.9 59.0 ± 27.0 0.003
Mean number of measurements 17.4 ± 6.4 17.6 ± 6.4 19.3 ± 7.5 0.005
Final eGFR (mL/min/1.73 m2) 88.6 ± 26.6 76.0 ± 26.6 55.9 ± 27.6 <0.001
Clinical Events during10-year follow-up
CVD a (%) 28 (7.6) 43 (17.8) 44 (24.7) <0.001
Interval from diabetes diagnosis (years) 5.8 ± 2.9 5.1 ± 2.7 4.8 ± 3.5 0.425
Change in CKD stage 1.0 ± 0.6 1.1 ± 0.6 1.5 ± 0.8 <0.001
Renal function impairment (%) 110 (29.3) 92 (36.8) 125 (62.8) <0.001
Interval from diabetes diagnosis (days) 3899 ± 1214 3710 ± 1285 3079 ± 1468 <0.001
CKD stage 4 or 5 (%) 35 (9.3) 29 (11.6) 22 (11.1) 0.620
Interval from diabetes diagnosis (days) 4366 ± 620 4311 ± 676 4272 ± 730 0.267
Total follow-up (days) 4488 ± 400 4424 ± 474 4413 ± 521 0.102
Abbreviations: HbA1c hemoglobin A1c, SBP systolic blood pressure, DBP diatolic blood pressure, SD standard deviation, eGFR estimated glomerular filtration rate,
CVD cardiovascular disease, CKD chronic kidney disease
aDefined as coronary artery disease or myocardial infarction, and ischemic stroke or transient ischemic attack
All significant change with p<0.05 had been italicized
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followed for 180 days revealed that the highest quintile
of the SD would increase the risk of end-stage renal
disease by 1.45-fold (CI 1.02–2.05) [20].
Many studies proved that an increase in VVV of SBP was
one of the factors which may contribute to the progression
of renal function deterioration [9, 10]. Mancia et al. sug-
gested that a steeper rate of blood pressure oscillations, in
addition to blood pressure levels, was related to end-organ
damage in hypertensive patients [21]. In hypertensive indi-
viduals, large arteries lose their compliance and became stiff
in hypertensive patients which resulted in less buffering of
blood pressure changes [22] and wider blood pressure oscil-
lation for any given change in the stroke volume, which
would be detected with the fluctuations of blood pressure
[23]. The initiation and progression of atherosclerosis of
the renal vasculature, resulted from the oscillatory shear
stress, could contribute to the impairment of renal function
[24]. However, these studies did not prove that high VVV
of DBP might be another factor result in the renal function
impairment in DM patients. Our 10-year long-term follow-
up results revealed that high VVV of DBP had detrimental
effects on the renal function of diabetic patients. The im-
pact of DBP in renal function ad been proved by many
studies. Brazy et al. stressed that reduced DBP, instead of
SBP or mean BP, to less than 90 mmHg could slow down
the rate of renal function deterioration [25]. Wight et al. re-
ported a positive correlation was observed between protein-
uria and DBP [26]. The discrepancy of our results from the
other VVV-related studies might come from the duration
of the study design. Most related reports included diabetic
patients in CKD stage 3 or higher and followed less than
5 years. Our study included intact renal function patients
who were in the first decade of DM diagnosed. The long-
term period of our study might be the most important fac-
tor that made high VVV of DBP stand out as a risk factor
of renal function impairment.
The retrospective nature of the present study and the sam-
ple size are two of the limitations of the present study. The
possibility of type 2 error existed. Other limitations are the
standardized procedure of blood pressure measurement and
the medication prescription record through 10-year follow-
up period. Certain classes of antihypertensive regimens, such
as non-β-blocker-based and non-rennin-angiotensin system-
based [27] or calcium channel blockers [28], had been prove
in reduction of the VVV of blood pressure with preservation
of end-organ damage in hypertensive patients. The anti-
hypertensive drugs in each patient were not consistent
throughout 10 years. It is very difficult to clarify the effect of
VVV amelioration of each category of anti-hypertensive
drugs, such as calcium channel blockers, which had been
proved to blunt the association between the VVV of BP and
renal function decline [4, 28]. Another limitation of the
present study is the absence of data regarding antihyperten-
sive prescription fill data and patients’ adherence to medica-
tion regimens. However, low antihypertensive medication
adherence explained only a small proportion of VVV of BP
[29], which implied that the absence of medication adher-
ence data does not have a major impact on the result of the
present study.
Nevertheless, this study has several strengths including the
one-decade follow-up of patients initially diagnosed with
DM with CKD and available information on demographic,
clinical, and long-term BP data. In addition, the use of the
electronic medical record database provided real-world
evidence on the status of hypertension control in the first
decade renal function prognosis of diabetic patients and
minimizes selection bias related to self selection into the
study. Our results prove that VVV of SBP and DBP has sig-
nificant prognostic value. However, prospective investigations
in stabilization of VVV of SBP and DBP are in need to iden-
tify the optimal therapeutic strategies and potentially modify
the clinical practice in hypertensive patients with type II DM.
Conclusions
In conclusion, the present study showed, in patients with
intact renal function, significant association between
high VVV of SBP and DBP with renal function decline
in the first decade of DM diagnosed.
Fig. 1 Kaplan-Meier plot of renal function impairment in newly
diagnosed type II diabetic patients for 10-year follow-up. Patients
was grouped into low VVV of SBP and DBP, high VVV of SBP or DBP,
and high VVV of SBP and DBP
Table 4 Multivariable Cox regression analysis of renal function
impairment
Hazard Ratio 95% CI P
Age at diabetes diagnosis (+1 year) 1.046 1.034–1.058 <0.001
Low VVV of SBP and DBP 1
High VVV of SBP or DBP 1.587 1.195–2.107 0.001
High VVV of SBP and DBP 2.773 2.128–3.612 <0.001
Abbreviations: SBP systolic blood pressure, DBP diastolic blood pressure,
SD standard deviation, CI confidence interval
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BMI: Body mass index; BP: Blood pressure; CKD: Chronic kidney disease;
CVD: Cardiovascular disease; DBP: Diastolic blood pressure; eGFR: estimated
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